Roth Capital initiates MediciNova at $6 price target
Roth Capital initiated coverage of MediciNova with a Buy rating and a $6.00 share price target, as cited by Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.